• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A qualitative framework of non-selection factors for cytoreductive nephrectomy.细胞减灭性肾切除术的非选择因素定性框架。
World J Urol. 2021 Sep;39(9):3359-3365. doi: 10.1007/s00345-021-03650-4. Epub 2021 Mar 29.
2
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.系统评价细胞减积性肾切除术在靶向治疗时代及以后的作用:转移性肾细胞癌的个体化治疗方法。
Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.
3
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.细胞减灭性肾切除术治疗肾细胞癌同步转移患者:来自国际转移性肾细胞癌数据库联盟的结果。
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
4
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.减瘤性肾切除术在转移性肾细胞癌中的独立肿瘤学作用:靶向治疗时代的预后特征
Urol Oncol. 2017 Apr;35(4):152.e13-152.e22. doi: 10.1016/j.urolonc.2016.10.013. Epub 2017 Jan 30.
5
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.新诊断转移性肾细胞癌患者的延迟细胞减少性肾切除术。
Eur Urol. 2020 Oct;78(4):615-623. doi: 10.1016/j.eururo.2020.04.038. Epub 2020 Apr 30.
6
Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.术前血清 De Ritis 比值与细胞减灭性肾切除术治疗转移性肾细胞癌患者的肿瘤学结局的关系。
Urol Oncol. 2020 Dec;38(12):936.e7-936.e14. doi: 10.1016/j.urolonc.2020.08.013. Epub 2020 Sep 19.
7
Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.转移性肾细胞癌的减瘤性肾切除术:采用多学科、算法驱动方法治疗的患者的结局
World J Urol. 2020 Dec;38(12):3199-3205. doi: 10.1007/s00345-020-03107-0. Epub 2020 Mar 3.
8
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.在具有良好的纪念斯隆凯特琳癌症中心(MSKCC)或东部肿瘤协作组(ECOG)预后特征的情况下,肾切除术可提高转移性肾细胞癌患者的总生存率。
Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.
9
Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.细胞减灭性肾切除术治疗同步转移性肾细胞癌的肿瘤学结果:单中心经验。
Clin Genitourin Cancer. 2018 Dec;16(6):e1189-e1199. doi: 10.1016/j.clgc.2018.07.030. Epub 2018 Aug 11.
10
The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.在真实世界队列中,细胞减灭性肾切除术对接受酪氨酸激酶抑制剂治疗转移性肾细胞癌患者的生存结局的影响。
Urol Oncol. 2020 Sep;38(9):739.e9-739.e15. doi: 10.1016/j.urolonc.2020.04.033. Epub 2020 Jun 21.

引用本文的文献

1
Development and validation of a prediction model for the prognosis of renal cell carcinoma with liver metastases: a population-based cohort study.肾细胞癌伴肝转移预后预测模型的开发与验证:一项基于人群的队列研究。
Front Med (Lausanne). 2024 Dec 3;11:1464589. doi: 10.3389/fmed.2024.1464589. eCollection 2024.
2
Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.转移性肾细胞癌患者能否从减瘤性肾切除术中获得生存益处?一项基于人群的研究。
J Cancer Res Clin Oncol. 2023 Sep;149(12):9657-9670. doi: 10.1007/s00432-023-04885-x. Epub 2023 May 25.

本文引用的文献

1
Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
Eur Urol. 2021 Mar;79(3):372-373. doi: 10.1016/j.eururo.2020.09.019. Epub 2020 Sep 24.
2
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较:SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
3
Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases.减瘤性肾切除术:评估CARMENA试验对真实世界国家癌症数据库病例的可推广性。
Eur Urol. 2019 Feb;75(2):352-353. doi: 10.1016/j.eururo.2018.10.054. Epub 2018 Nov 9.
4
Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.主动监测低危前列腺癌:欧洲泌尿外科学会 2018 年立场声明。
Eur Urol. 2018 Sep;74(3):357-368. doi: 10.1016/j.eururo.2018.06.008. Epub 2018 Jun 22.
5
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.舒尼替尼单药治疗或肾细胞癌转移患者肾切除术后的治疗。
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
6
Cytoreductive Nephrectomy - Patient Selection Is Key.减瘤性肾切除术——患者选择是关键。
N Engl J Med. 2018 Aug 2;379(5):481-482. doi: 10.1056/NEJMe1806331. Epub 2018 Jun 3.
7
Renal Mass and Localized Renal Cancer: AUA Guideline.肾脏肿块和局限性肾细胞癌:AUA 指南。
J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.
8
Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.小肾肿瘤的治疗管理:美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17.
9
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.转移性肾细胞癌的主动监测:一项前瞻性2期试验。
Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.
10
Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.全面描述细胞减灭性肾切除术的围手术期并发症。
Eur Urol. 2016 Jan;69(1):84-91. doi: 10.1016/j.eururo.2015.05.022. Epub 2015 Jun 1.

细胞减灭性肾切除术的非选择因素定性框架。

A qualitative framework of non-selection factors for cytoreductive nephrectomy.

机构信息

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA.

Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.

出版信息

World J Urol. 2021 Sep;39(9):3359-3365. doi: 10.1007/s00345-021-03650-4. Epub 2021 Mar 29.

DOI:10.1007/s00345-021-03650-4
PMID:33779820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8478968/
Abstract

PURPOSE

Cytoreductive nephrectomy (CN) benefits a subset of patients with metastatic renal cell carcinoma (mRCC), however proper patient selection remains complex and controversial. We aim to characterize urologists' reasons for not undertaking a CN at a quaternary cancer center.

METHODS

Consecutive patients with mRCC referred to MSKCC urologists for consideration of CN between 2009 and 2019 were included. Baseline clinicopathologic characteristics were used to compare patients selected or rejected for CN. The reasons cited for not operating and the alternative management strategies recommended were extrapolated. Using an iterative thematic analysis, a framework of reasons for rejecting CN was designed. Kaplan-Meier estimates tested for associations between the reasons for not undertaking a CN and overall survival (OS).

RESULTS

Of 297 patients with biopsy-proven mRCC, 217 (73%) underwent CN and 80 (27%) did not. Median follow-up of patients alive at data cut-off was 27.3 months. Non-operative patients were older (p = 0.014), had more sites of metastases (p = 0.008), harbored non-clear cell histology (p = 0.014) and reduced performance status (p < 0.001). The framework comprised seven distinct themes for recommending non-operative management: two patient-fitness considerations and five oncological considerations. These considerations were associated with OS; four of the oncological factors conferred a median OS of less than 12 months (p < 0.001).

CONCLUSION

We developed a framework of criteria by which patients were deemed unsuitable candidates for CN. These new insights provide a novel perspective on surgical selection, could potentially be applicable to other malignancies and possibly have prognostic implications.

摘要

目的

细胞减灭性肾切除术(CN)使一部分转移性肾细胞癌(mRCC)患者受益,但合适的患者选择仍然复杂且存在争议。我们旨在描述一家四级癌症中心的泌尿科医生不进行 CN 的原因。

方法

连续纳入 2009 年至 2019 年期间在 MSKCC 泌尿科医生处考虑进行 CN 的 mRCC 患者。比较选择或拒绝 CN 的患者的基线临床病理特征。推断出未手术的原因和推荐的替代治疗策略。使用迭代主题分析,设计了拒绝 CN 的原因框架。Kaplan-Meier 估计检验了不进行 CN 的原因与总生存(OS)之间的关联。

结果

在 297 例经活检证实的 mRCC 患者中,217 例(73%)接受了 CN,80 例(27%)未接受。截止数据截止时存活患者的中位随访时间为 27.3 个月。非手术患者年龄较大(p=0.014),转移部位较多(p=0.008),存在非透明细胞组织学(p=0.014)和较低的体能状态(p<0.001)。该框架包含了推荐非手术治疗的七个不同主题:两个患者健康状况考虑因素和五个肿瘤学考虑因素。这些考虑因素与 OS 相关;其中四个肿瘤学因素的中位 OS 小于 12 个月(p<0.001)。

结论

我们制定了一个框架,根据该框架,患者被认为不适合进行 CN。这些新的见解为手术选择提供了新的视角,可能适用于其他恶性肿瘤,并可能具有预后意义。